Suzetrigine

Suzetrigine (VX-548; trade name Journavx) is the first selective inhibitor of the NaV1.8 voltage-gated sodium channel to receive regulatory approval, granted by the United States Food and Drug Administration on 30 January 2025 for the treatment of moderate-to-severe acute pain in adults. The compound represents a mechanistically novel analgesic class, acting by allosteric binding to the extracellular S3-S4 loop of voltage-sensing domain 2 (VSD2) of the NaV1.8 channel, where a KKGS amino acid sequence unique to this subtype confers greater than 31,000-fold selectivity over the other nine human voltage-gated sodium channel isoforms. NaV1.8, encoded by the SCN10A gene, is expressed almost exclusively in peripheral nociceptive neurons of the dorsal root ganglia, where it contributes more than 70 percent of the depolarizing current during pain-signaling action potentials. Suzetrigine stabilizes the channel in its closed (resting) state through tonic inhibition that is independent of channel opening frequency, thereby reducing pathological nociceptor hyperexcitability without affecting cardiac, central nervous system, or skeletal muscle sodium channels.

The compound emerged from a multi-year medicinal chemistry program at Vertex Pharmaceuticals that progressed through the predecessors VX-128 and VX-150 before arriving at VX-548, which demonstrated an in vitro IC50 of 0.68 nanomolar against human NaV1.8 with negligible activity (IC50 greater than 10,000 nanomolar) against all other NaV subtypes. In Phase 2 randomized controlled trials in postoperative bunionectomy and abdominoplasty pain, suzetrigine at a 100 mg loading dose followed by 50 mg every 12 hours produced statistically significant reductions in the time-weighted sum of pain intensity difference over 48 hours (SPID48) compared to placebo (37.8-point and 36.8-point superiority, respectively). In the pivotal Phase 3 NAVIGATE-1 (bunionectomy, N = 1,073) and NAVIGATE-2 (abdominoplasty, N = 1,118) trials, suzetrigine achieved statistically significant superiority over placebo on SPID48 (p = 0.0002 and p < 0.0001, respectively), with analgesic efficacy broadly comparable to hydrocodone/acetaminophen but without opioid-class adverse effects including respiratory depression, sedation, or abuse liability.

Pharmacokinetics are characterized by oral administration with a time to peak plasma concentration of approximately 3 hours in the fasted state, extensive tissue distribution (volume of distribution approximately 495 liters), 99 percent plasma protein binding, and hepatic metabolism predominantly through CYP3A enzymes to the active metabolite M6-SUZ (3.7-fold less potent than parent compound). The terminal elimination half-life of suzetrigine is 23.6 hours, and that of M6-SUZ is 33.0 hours, supporting twice-daily maintenance dosing. Excretion occurs through both fecal (49.9 percent) and urinary (44.0 percent) routes. The compound is contraindicated with strong CYP3A4 inhibitors and in severe hepatic impairment (Child-Pugh Class C). The most common adverse events in clinical trials were nausea, headache, dizziness, constipation, pruritus, muscle spasms, and rash, all predominantly mild to moderate in severity. No respiratory depression, physical dependence, or abuse potential has been identified in clinical or preclinical assessments.

This monograph documents the chemistry, structural pharmacology, mechanism of action, comprehensive pharmacokinetics, preclinical and clinical evidence base, regulatory history, sourcing and handling considerations, drug interaction profile, adverse-event signal, and a structured comparative assessment of five alternative analgesic approaches (VX-150, hydrocodone/acetaminophen, pregabalin, celecoxib, and lidocaine 5% patch) against suzetrigine on five competency standards.